The Problem with 'Indica' and 'Sativa' on Cannabis Labels: New Report

Spread the love

<![CDATA[

The inadequacies of the “indica” and “sativa” labels have long been discussed and debated in the cannabis market. With the advent of a booming legal industry, those terms are more scrutinized than ever before—and yet they are still widely used for marketing purposes. Indica strains leave the user feeling relaxed and sleepy, as the lore has it, has sativa strains provide the user a refreshing burst of energy and creativity.

It sounds enticing as a roadmap for cannabis experiences. But it falls short of reality.

Dr. Sean Myles and his co-authors confirmed as much with their research paper, published in Nature Plants, which examines whether that indica-sativa dichotomy matches what users might experience with different chemovars. 

After analyzing 297 samples provided by Bedrocan International in the Netherlands, Myles and the Dalhousie University team determined that “Sativa- and Indica-labelled samples were genetically indistinct on a genome-wide scale.” The flower samples were tagged with labels along a five-point scale, such as one might see in a licensed dispensary: indica, indica-dominant, hybrid, sativa-dominant, sativa. 

Genetic testing revealed that those terms don’t correlate in any meaningful way with the effect of the plant’s chemistry.

“All we’re doing in our study is demonstrating the degree to which these labels are good predictors of what’s in your package.,” Myles said in a phone interview. “What are you actually getting? The answer is they’re terrible predictors. It is not uncommon to get one sativa one week, and the next week you go to get [a] sativa [strain] because you liked it, but it’s chemically and genetically more similar to things labeled indica.”

This is a problem. As longtime consumers and the “canna-curious” alike enter the regulated landscape, this marketing disfunction poses an issue for not only brand affinity and consumer interest but, to an extent, public safety. People want to know that what they’re purchasing is what they mean to purchase.

Myles, whose team works mostly with apples and grapes, said it’s a simple matter of consistency.

“With any other agricultural organism, when you put a name on something, it actually means something,” he said. “And with cannabis this is not the case.”

Anyone interested in the wine market can see the relevant comparison.

“If you think about it, in agriculture, there’s really only one other organism, other than apples and grapes, where the public is interested in the actual genetic identity of the plants—right down to the cultivar level,” Myles said. “People know what a Pinot Noir is or a Cabernet Sauvignon. Those are like unique genetic identities. They know a McIntosh apple or a Honeycrisp apple, right? But name a carrot.”

Increasingly, brands are developing marketing language around mood, effect and dosage—using words like “rest” or “bliss” to convey something closer to the anticipated experience. Cannabinoid ratios are becoming more visible on product labels. And product lines are being formulated to run the gamut from heavier, medical-level dosages to microdosages. Even terpene profiles are making their way onto labels, and that’s one important takeaway from the Dalhousie University research.

In the paper, the authors point to terpenes as a far more predictable point of measurement. A cannabis chemovar’s terpene profile will tell a prospective consumer far more about the potential effects—whether cerebral and relaxing or spritely and creative, or anything else—than old chestnuts like “indica” and “sativa.”

This is an opportunity for brands to engage the consumer on a level that, by and large, the consumer has already shown a willingness to learn more about. Myles added with a note of pleasant surprise that many consumers know the word “myrcene,” something that until recently has mostly been relegated to plant biology talk.

He and the team aren’t being prescriptive in their paper, however; they are merely using research to back up the growing concern around some of the cultural shorthand in cannabis.

“I’m unsure what the recommendation should be in terms of what better labeling practices should be,” Myles said. “But certainly misinformation is not the way to go.”

 

]]>
Source: One

Schaka

Related Posts

Cannabidiol Induces Cell Death in Human Lung Cancer Cells and Cancer Stem Cells

Cannabidiol Does Not Cause Significant Changes to Working Memory Performance in the N-Back Task

Vasoprotective Endothelial Effects of Chronic Cannabidiol Treatment and Its Influence on the Endocannabinoid System in Rats with Primary and Secondary Hypertension

Cannabidiol Suppresses Angiogenesis and Stemness of Breast Cancer Cells by Downregulation of Hypoxia-Inducible Factors-1alpha

Signez la pétition !!!

 

846 signatures

Pétition ASBL Cannabis Belgique

Pourquoi une pétition ?

Nous sommes des personnes qui en avons assez de devoir aller dans la rue et avoir affaire à des réseaux criminels sans savoir où cela va nous conduire par après.

Nous sommes des personnes ayant des maladies, qui pour certaines sont rares, et utilisant pour médication le cannabis sous diverses formes (CBD,THC,THCv,CBDa,,,) sous l'accord de notre médecin.

Nous sommes des personnes responsables et honnêtes qui avons une vie épanouie et sans problèmes de vie ou sociaux.

Nous avons également une passion pour la plante de cannabis en elle-même et la cultiver est notre bonheur. De plus, nous pouvons nous soigner avec notre médication sans avoir peur des produits ou autres additifs contenus dans une plante que l'on peut trouver autre part.

Nous souhaitons pouvoir avoir notre médicament dans les normes de la santé publique, car un cannabis sain aide à réduire les frais de santé parfois conséquents pour la collectivité et le malade lui-même.

Nous sommes également des personnes responsables avec un rôle dans la société qui en avons assez d’être considérés comme des « hippies ou autres drogués », nous avons juste choisi notre médication et celle-ci a apporté les preuves de son efficacité dans le monde.

Nous connaissons déjà les produits dérivés comme le CBD et le THC que nous maîtrisons pour nous aider dans notre maladie « Je précise que nous ne sommes pas médecin et que nous nous basons sur 20 ans d’expérience médicale du cannabis des membres de notre ASBL et l'avis du médecin de famille ».

Nous désirons simplement ne plus nous cacher, et pouvoir aider les autres personnes le souhaitant.

Nous somme soucieux des ados et de la prévention à leur égard. Effectivement, nous sommes les acteurs parfaits pour répondre aux questions qu’ils se posent vu notre expérience cannabique et, de plus, nous pourrons leur expliquer les risques qu’ils encourent en achetant du cannabis dans la rue.

Le projet complet peut être demandé via mail " info@mcb.care " et sur le site internet : " http://mcb.care "

@ASBL McB

**votre signature**

Partagez avec vos amis

Articles récents

Catégories